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The peroxisome proliferator-activated receptors (PPARs)
belong to the ligand-inducible nuclear hormone receptor
superfamily including three major members: PPAR𝛼 (also
called NR1C1), PPAR𝛽/𝛿 (also called NR1C2), and PPAR𝛾
(also called NR1C3). Despite several similarities, each PPAR
isoform shows specific functions likely due to different
biochemical properties, variable tissue distribution, and dif-
ferential responses to different ligands. PPAR transcriptional
activity can be modulated through a nongenomic cross
talk with phosphatases and kinases, including ERK1/2, p38-
MAPK, PKA, PKC, AMPK, and GSK3. PPARs can form
heterodimers with retinoid X receptor (RXR) modulat-
ing the expression of genes involved in lipid metabolism,
adipogenesis, maintenance of metabolic homeostasis, and
inflammation and inducing also anticancer effects in a variety
of human tumors. Although all PPAR isoforms are impli-
cated in several metabolic syndromes, PPAR𝛾 seems to be
mostly involved in tumorigenesis regulation via activation
of different pathways. Therefore, the modulation of PPAR
signaling pathways could be a potential novel strategy to
inhibit carcinogenesis and tumor progression. PPAR𝛾 can
be activated by natural ligands, such as fatty acids and
their derivatives, as well as synthetic ligands, such as thia-
zolidinediones (TZDs), including ciglitazone, rosiglitazone,
troglitazone, and pioglitazone. TZDs have been shown to be
a class of drugs with potent insulin-sensitizing activity used
to improve lipid and glucosemetabolism in obesity and type 2
diabetes via PPAR. Since accumulating evidence highlighted
the role of PPAR signaling in carcinogenesis, type 2 diabetes,
and othermetabolic disorders, such as obesity, understanding
the potential molecularmechanisms underlying the interplay
between metabolism, PPAR signaling, and cancer may rep-
resent an interesting research field for the development of
novel strategies useful for the prevention and treatment of
cancer. Since there exists a strong correlation between obesity
and diabetes and both have been also shown to increase
cancer risk, the identification of the molecular mechanisms
by which PPAR modulates these events may help us to better
understand how the diet may affect the cancer susceptibility.
In this special issue we have assembled different studies
describing possible intracellular pathways involved in these
processes, in order to increase the current knowledge about
the correlation between metabolic syndromes and cancer via
activation of different PPAR signaling pathways. In particular,
our endpoint was to provide an overview about the potential
roles of PPARs in modulating the cancer risk induced by
metabolic disorders such as diabetes and obesity. Here, we
gathered 1 original research paper and 9 review articles
that describe and discuss the various functions of PPARs in
the context of several metabolic alterations associated with
different types of cancer.
In our review article titled “Potential Role of ANGPTL4
in the Cross Talk between Metabolism and Cancer through
PPAR Signaling Pathway,” we speculated and discussed
the potential role of ANGPTL4 as key player in mediat-
ing the cross talk between metabolic syndromes, such as
diabetes and obesity, and cancer through regulation of its
expression by PPARs. Indeed, since ANGPTL4 is involved
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in several metabolic conditions, both physiological and
pathological, including angiogenesis, glucose homoeostasis,
lipid metabolism, and tumorigenesis, we hypothesized that
its transcriptional regulation by PPARs could represent a
gateway between obesity, insulin sensitivity, and cancer.
The review article by S. G. Vitale et al. “Peroxisome
Proliferator-Activated Receptor Modulation during
Metabolic Diseases and Cancers: Master and Minions”
provided an overview on the different roles of PPARs
in control of the expression of genes involved in energy
homeostasis, cell proliferation, and apoptosis, discussing the
involvement of these nuclear receptors in tumorigenesis and
development of metabolic diseases.
B. B. Merchan and collaborators in their review article
titled “Commonalities in the Association between PPARG
and Vitamin D Related with Obesity and Carcinogenesis”
have focused on the recent advances that led to hypothesizing
a possible cross talk between PPARG, Vitamin D system,
obesity, and cancer, suggesting a close cooperation between
the vitamin D/VDR system and PPARG signaling in order to
maintain a correct metabolic homeostasis. Interestingly, the
authors reported several studies describing how the shortage
of Vitamin D and decrease in PPARG levels may be involved
in obesity and cancer development.
In another manuscript titled “PPAR Gamma in Neu-
roblastoma: The Translational Perspectives of Hypoglycemic
Drugs” S. Vella et al., by reviewing literature data, discussed
the potential beneficial effects of hypoglycemic drugs, such as
thiazolidinediones and metformin, in treatment of neurob-
lastoma patients.
A noteworthy contribution to this special issue was the
review article titled “PPAR𝛿 as a Metabolic Initiator of
Mammary Neoplasia and Immune Tolerance” by R. I. Glazer
describing the involvement of PPAR𝛿 in the initiation and
promotion of mammary tumorigenesis through its pivotal
role in regulating metabolism, inflammation, and immune
tolerance.
An interesting review article by T. Mello and colleagues
titled “PPARs andMitochondrial Metabolism: FromNAFLD
toHCC” described the functions of PPARs in themodulation
of liver mitochondrial metabolism during the progression
from nonalcoholic fatty liver disease to hepatocellular car-
cinoma, hypothesizing the possibility, in future, of using
new therapeutic approaches able to selectively target the fuel
requirements of HCC.
In the review article titled “MicroRNAs-Dependent Reg-
ulation of PPARs in Metabolic Diseases and Cancers,” D.
Portius et al. stressed out the miRNA-mediated regulation of
PPARs in the context of metabolic disorders, inflammation,
and cancer. Moreover, the authors evaluated the reciprocal
control of miRNA expression by PPARs, to finally specu-
late about the therapeutic potential of modulating PPAR
expression/activity by pharmacological compounds targeting
miRNAs.
Instead, S. P. Lakshmi et al. provided a review article
titled “PPAR Agonists for the Prevention and Treatment of
Lung Cancer,” where authors described the role of PPAR𝛼,
PPAR𝛽/𝛿, and PPAR𝛾 in lung cancer pathogenesis and
dissected the current literature on the multifaceted effects of
PPAR agonists in lung cancer treatment. Finally, the authors
discussed how PPAR ligands may be used in the context of
novel therapeutic strategies against this disease.
In “Deciphering the Roles of Thiazolidinediones and
PPAR𝛾 in Bladder Cancer”M. Chiu and colleagues discussed
how some thiazolidinediones, synthetic ligands of PPAR𝛾
used in the treatment of diabetes mellitus type 2, could
significantly increase the risk of developing bladder cancer.
Lastly, A. A. Koronowicz and collaborators in their
research paper titled “Fatty Acids of CLA-Enriched Egg
Yolks Can Induce Transcriptional Activation of Peroxisome
Proliferator-Activated Receptors in MCF-7 Breast Cancer
Cells” investigated the effects in vitro of fatty acids fromCLA-
enriched egg yolks (EFA-CLA) acting as potential ligands for
PPAR receptors in breast cancer cell line MCF-7. The authors
showed that PPAR-responsive genes can be regulated by
EFA-CLA, leading to a reduction of tumor cell proliferation,
with a greater influence by EFA-CLA treatment compared to
nonenriched FAs or single synthetic CLA isomers.
In conclusion, understanding the different roles of PPARs
in the cross talk between metabolic syndromes, such as
diabetes and obesity, and cancer could help us, in future, to
identify novel potential therapeutic targets involved in the
cancer development and different cancer-related metabolic
syndromes. This special issue, thanks to the interesting
contributions by various authors, attempts to provide a small
overview of the studies present in literature regarding the
involvement of PPAR Signaling Pathway in carcinogenesis
and metabolic alterations, enriching the current knowledge
in the field and opening up new roads towards multidis-
ciplinary approaches that promote the interaction between
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